Clinical Pharmacist-Led Cardiovascular Risk Assessment in Patients With Chronic Kidney Disease (CRICKD)
Key facts
- Who runs it
- Marmara University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 150 people enrolled
- Started
- 3 Jan 2022
- Ended
- 15 Mar 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- Clinical Pharmacist-Led Pharmaceutical Care
- Standard Medical Care (SMC)
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 74 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adults aged 18-74 years
- Patients diagnosed with chronic kidney disease (CKD), including those receiving dialysis
- Patients hospitalised in the internal medicine clinic
- Patients who agreed to participate in the study
Who cannot take part
- Patients with dementia or Alzheimer's disease
- Patients who did not agree to participate in the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Chronic kidney disease (CKD) is a long-term condition that can increase the risk of cardiovascular diseases, such as heart attacks and strokes. People with CKD often have other health conditions and take several medications, which can make following treatment plans challenging. Clinical pharmacists may help these patients by reviewing their medications, providing education, and supporting medication adherence and cardiovascular risk management.
Read full original descriptionShow less
This study evaluated the impact of a clinical pharmacist-led pharmaceutical care program on cardiovascular risk, medication adherence, and quality of life in hospitalized adults with CKD.
The study was conducted at a research and training hospital in Istanbul, Türkiye, with a planned six-month follow-up. A total of 150 patients were initially enrolled and assigned to either an intervention group or a control group. Due to deaths, withdrawal from the study, and loss to follow-up, 101 patients were included in the final analysis.
Patients in the control group received standard medical care. Patients in the intervention group received additional pharmaceutical care from a clinical pharmacist, including medication review, education about CKD and cardiovascular risk factors, counseling on medication adherence and lifestyle changes, and follow-up counseling.
The study assessed cardiovascular risk using a Framingham-based risk model. Medication adherence and health-related quality of life were evaluated using standardized questionnaires. Medication regimen complexity and relevant clinical measurements were also assessed.
The findings showed that cardiovascular risk scores decreased in both groups during the study period. Medication adherence increased in both groups, from 59.2% to 75.5% in the control group and from 75.0% to 88.5% in the intervention group. However, the difference in medication adherence between the groups at follow-up was not statistically significant. Quality-of-life scores were significantly higher in the intervention group at both baseline and follow-up. A weak negative correlation was observed between medication regimen complexity and quality of life, indicating that greater medication complexity was associated with lower quality-of-life scores.
Overall, the findings suggest that clinical pharmacist-led pharmaceutical care may support medication management in patients with CKD. However, the study did not demonstrate statistically significant differences between groups in medication adherence or cardiovascular risk outcomes. Further studies with larger samples and adequate follow-up are needed to clarify the effects of pharmacist-led interventions in this population.
The 2 groups in the trial
- Clinical Pharmacist-Led Pharmaceutical CareTreatment being tested
Participants in this group received standard medical care in addition to a clinical pharmacist-led pharmaceutical care program. The intervention included medication review, education about chronic kidney disease and cardiovascular risk factors, counselling on medication adherence, and advice on lifestyle modifications, including dietary recommendations and smoking cessation. Follow-up counselling was provided during the six-month study period.
- Standard Medical Care (Control Group)Treatment being tested
Participants in this group received standard medical care without the additional clinical pharmacist-led pharmaceutical care programme.
Treatment: Standard Medical Care (SMC)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Clinical Pharmacist-Led Cardiovascular Risk Assessment on Medication Adherence and Quality of Life in Patients With Chronic Kidney Disease: A Randomised Controlled Study
- Record updated
- 12 November 2026